Background: The WBRTMel trial is a multinational, open-label, phase III randomised controlled trial comparing whole brain radiotherapy (WBRT) to observation following local treatment of one to three melanoma brain metastases with surgery and/or stereotactic irradiation. The primary trial endpoint was to determine the effect of adding WBRT to local treatment on distant intracranial control, and the secondary endpoints were neurocognitive function, quality of life (QoL), performance status, overall survival, death from intracranial causes, death from melanoma and cost-effectiveness.
Introduction

Preface
Brain metastases are a common cause of death in patients with melanoma. The use of whole brain radiotherapy (WBRT) after excision and/or stereotactic radiosurgery (SRS) for melanoma brain metastases is variable because of the lack of high-quality evidence to guide practice. The trial's rationale, feasibility and protocol were previously published [1] [2] [3] . In brief, the primary trial endpoint was to determine the effect of adding WBRT to local treatment on distant intracranial control, and the secondary endpoints were neurocognitive function (NCF), quality of life (QoL), performance status, overall survival, death from intracranial causes, death from melanoma and cost-effectiveness. In concordance with clinical trial requirements, the study was prospectively registered (ACTRN12607000512426 and NCT01503827). The trial completed the target accrual in September 2017, and the final participant will be followed up for at least 24 months.
Purpose of the analyses
The statistical analyses will assess the clinical endpoints and safety of WBRT compared with the observation following excision and/or SRS.
Study objectives and endpoints
Study objectives
This trial aims to improve the treatment of brain metastases for patients with stage IV melanoma by using WBRT to improve disease control and maintain cognitive performance and QoL.
Endpoints
Primary endpoint
The primary endpoint of the study is defined as distant intracranial failure within 12 months of randomisation. Distant intracranial failure is evaluated through magnetic resonance imaging (MRI) assessment, as reported by participating institutions, and is defined as new lesions appearing 1 cm or more from previous index metastases, coded as a binary outcome of success or failure.
Key secondary endpoint
The main NCF endpoint is decline in the mean raw score of the Hopkins Verbal Learning Test-Revised (HVLT-R) with Delayed Recall at 4 months, using (1) relative change defined as ΔHVLT = 100*(HVLT B -HVLT F ) ÷ HVLT B , where indexes B = baseline and F = a pre-specified follow-up time point [4] , and (2) Reliable Change Index (RCI) defined as a decline of ≥ 5 points from baseline [5] .
Secondary endpoints
Several secondary endpoints are assessed during the study.
Neurocognitive decline will be computed for HVLT-R (Total Recall, Delayed Recall, Delayed Recognition), Controlled Oral Word Association Test, Trail Making Test Parts A and B, Stroop Color and Word Test (Adult Version, Stroop Color, Stroop Word, Stroop Color-Word, Stroop Interference), and Digit Span (total score) [6, 7] . Time to cognitive failure is defined as the time from randomisation to date of first cognitive failure on any of the NCF tests or death for patients who die due to an intracranial cause prior to assessment or NCF for patients who were alive but could not complete the neurocognitive test due to neurological disability. Cognitive failure for patients with NCF assessment scores will be analysed using both raw and standardised scores and defined by a significant change in the RCI. Patients without neurognitive failure are censored at their last date of contact. Distant intracranial failure within 3, 6 and 9 months of follow-up and over the entire study period (see primary endpoint definition)
Time to distant intracranial failure as determined by MRI
This is defined as the time to recurrence of disease to a distance of 1 cm or more from previously treated metastases from the date of randomisation. It is measured by the time difference between the randomisation MRI and intracranial failure MRI identifying recurrence.
Time to local intracranial failure as determined by MRI
This is defined as the time to recurrence of disease within 1 cm of previously treated metastases from the date of randomisation. It is measured by the time difference between the randomisation MRI and intracranial failure MRI identifying recurrence. Local intracranial failure rates within 3, 6, 9 and 12 months of follow-up and over the entire study period will also be computed.
Time to overall (first distant or local) intracranial failure
This is determined through MRI from observable deterioration and is defined as the time to the first intracranial recurrence of disease anywhere (distant or local) from randomisation. Overall intracranial failure rates within 3, 6, 9 and 12 months of follow-up and over the entire study period will also be computed.
Time to deterioration in performance status as measured by the Eastern Cooperative Oncology Group (ECOG) Performance Status This is defined as the time that elapses between randomisation and the first recorded worsening in ECOG Performance Status. This increase is measured from the randomisation visit ECOG Performance Status score.
QoL outcomes
The outcomes are measured using the European Organisation for the Research [10] ; (2) the five dimensions questionnaire (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), where each dimension has five levels (no problems, slight problems, moderate problems, severe problems and extreme problems).
In addition to associated dimension/items used as QoL outcomes, time to deterioration in health-related QoL parameters will also be derived and compared between groups. The deterioration in health-related QoL outcomes will be measured by the EORTC QLQ-C30 and QLQ-BN20 questionnaires. The primary QoL endpoint will be time to deterioration in role function from randomisation, with deterioration defined as a decrease of ≥10 points on a 0-100 scale persisting for at least 4 weeks. Secondary endpoints will be time to deterioration in global QoL, drowsiness, communication difficulties, motor dysfunction and social function items/domains.
Survival endpoints
Two sets of survival endpoints are considered: (1) overall survival defined as time to death due to any cause and (2) disease-specific outcomes which include time to death due to intracranial disease and other melanoma-specific cause. Survival time is assessed from date of randomisation to that of death. Patients remaining alive or lost to follow-up will be censored at the date of last contact.
Neurocognitive assessments
The Global Deficit Score (GDS) derived from NCF tests at each assessment point [11] . Cognitive impairment is defined as a GDS of ≥ 0.5 [12] .
Tertiary endpoints
Although not statistically powered for these endpoints, this trial will provide a unique opportunity to assess observation vs. hippocampal avoidance (HA-WBRT) vs. WBRT in a prospective fashion for NCF outcomes. In particular, this analysis will add to the ongoing debate on the impact of WBRT on NCF and intracranial control [13, 14] .
The following variables will be considered:
Mean relative NCF change from baseline at 2, 4, 6 and 12 months based on: HVLT-R Delayed Recall HVLT-R Total Recall HVLT-R Delayed Recognition. Global cognitive deterioration survival based on the definition of cognitive impairment of 1 standard deviation (SD) in at least one of the following cognitive tests: HVLT-R, Trail Making Test or Controlled Oral Word Association.
The following definitions of cognitive impairment will also be explored: ○ 2 SD decline in at least one cognitive test ○ 1 SD decline in at least two cognitive tests ○ 2 SD decline in at least two cognitive tests.
Safety outcomes
Adverse events (AEs) and any AE reported as a serious adverse event (SAE) will be included in this analysis. An AE is any adverse change (developing or worsening) from the patient's pre-treatment condition, including intercurrent illness. AEs are to be recorded at the baseline visit and then every 2 months at the follow-up visits or until the patient experiences distant intracranial failure.
In this trial an SAE is defined as any untoward medical occurrence which occurs during or within 90 days of randomisation and which: 
Study methods
General study design and plan
This is a multinational, open-label, stratified, 2-arm parallel phase III trial. Figure 1 shows the schema for the trial.
Inclusion and exclusion criteria and general study population
Patient population
Patients were recruited from participating multidisciplinary melanoma centres. Patients were identified via routine scanning demonstrating asymptomatic metastases or following investigation of intracranial symptoms.
Inclusion criteria
Patients were included in the study only if they met all of the following criteria:
1. One to three (1-3) intracranial metastases on MRI from melanoma, locally treated with either surgical excision and/or SRS. It was assumed that the metastases were melanoma if the patient had documented histological concurrent extracranial disease that had already made the patient stage IV. If the cerebral lesion(s) were the first presentation of stage IV disease, then one metastasis had to be histologically proven to be melanoma for the patient to be included in the study. Estimated glomerular filtration rate (eGFR) was adequate at the discretion of the radiologist and capable of having gadolinium-containing contrast medium for MRI (as per practice guidelines). 6. Completion of local treatment of all these metastases no more than 6 weeks prior to randomisation. 7. An ECOG Performance Status between 0 and 2 at randomisation. 8. Computed tomography (CT) or positron emission tomography (PET) scan of chest, abdomen and pelvis as a minimum prior to randomisation. Scans must have been taken within 12 weeks of randomisation. 9. Serum lactate dehydrogenase (LDH) level must have been ≤2× upper limit of normal. 10. Was able to provide written informed consent. 
Exclusion criteria
Patients were excluded from the study for any of the following reasons: In order to be eligible for the main study, patients must have cleared all of the preceding inclusion and exclusion criteria. If centres had access to intensity-modulated radiotherapy (IMRT) for patients with brain metastasis, randomisation could occur before local radiotherapy treatment to allow for the use of simultaneous integrated boost during WBRT (see the Interim analyses and data monitoring section). In addition, patients were excluded from the neurocognitive and QoL aspects of the study if their fluency of (oral and written) English was less than year 8 standard.
Randomisation and blinding
Patients were randomised at a 1:1 ratio using an interactive voice response (randomisation) system (IVRS). Randomisation was stratified by the following factors:
Number of cerebral metastases (1 only vs. > 1) Presence or absence of extracranial disease (seen on clinical review and/or imaging) Centre Sex (male vs. female) Planned whole brain radiotherapy dose, 30 Gray in 10 fractions (30 Gy/10#) or higher Age (< 65 or ≥ 65 years old)
Study variables
All parameters and their timing of collection are summarised in Table 1 .
Sample size
Assuming the proportion of patients having distant intracranial metastases at 12 months post-randomisation would be 55% in the local control arm (surgery and/or SRS) and 33% in the WBRT arm, a total of 220 patients provided more than 84% power to detect the absolute reduction of 22%, allowing for up to 10% non-compliance and a two-sided alpha of 5%.
The initial sample size was based on a total sample size of 200 to achieve 80% to reach the study primary objective. However, modern radiation therapy technologies to spare the hippocampus during WBRT became available in some centres during the study. In addition, phase 2 data showed that HA-WBRT was superior in terms of NCF outcomes, a secondary but important endpoint of the study. The investigators felt that if the option of HA-WBRT was not included, accrual would suffer. Therefore, the sample size was increased by protocol amendment from the initial 200 to 220 to enable the recruitment of a total of 27 patients treated with HA-WBRT. A sample of 27 patients treated with HA-WBRT would achieve 80% power to detect a mean relative decline ≤7.5% against 30% mean relative decline in a historical control from baseline to 4 months. The sample size calculation assumed an estimated SD of 0.41, and the level of significance (alpha) was set to 5% using a one-sided Wilcoxon test assuming that the actual distribution is normal.
At the time of the protocol amendment, 27 January 2016, 190 patients were enrolled in the study; among them 16 had HA-WBRT. Therefore, 11 extra HA-WBRT patients were needed. We expected to accrue these additional 11 HA-WBRT patients by enrolling a further 30 patients, bringing the total sample size to 220.
General considerations
The analysis principles are as follows:
1. All analyses will be conducted on an intention-totreat basis. 2. All randomised patients will be analysed in the group to which they were assigned regardless of protocol violations. The only exception will be patients whose consent to use their data in the analysis is withheld or withdrawn. 3. All tests will be two-sided with a nominal level of alpha of 5%. 4. Treatment effect estimated as difference in means, odds ratio, hazard ratio or subdistribution hazard and their 95% confidence interval (CI) will be reported for all outcomes. 5. Adjusted analyses including the stratification factors will be performed as sensitivity analyses. 
. Subgroup analyses will be carried out irrespective of whether there is a significant effect of treatment on outcome. 7 . P values will not be adjusted for multiplicity.
However, the outcomes are clearly categorised by degree of importance (primary to tertiary), and a limited number of subgroup analyses are prespecified. 8. All summary tables will be annotated with the total population size relevant to each treatment group. 9. P values ≥ 0.001 will be reported to three decimal places; P values less than 0.001 will be reported as '< 0.001'. The mean, SD and any other statistics other than quantiles will be reported to one decimal place greater than the original data. Quantiles, such as median, or minimum and maximum will use the same number of decimal places as the original data. Estimated parameters, not on the same scale as raw observations (e.g. regression coefficients), will be reported to three significant figures. 10. Analyses will be conducted primarily using SAS, version 9.4 or later and R 3.4.1 or later.
Analysis population
The final analysis will include all patients who were randomised and have all baseline assessments performed.
Subgroups
The primary endpoint and the secondary endpoints (excluding the key secondary endpoint) will be assessed for the following subgroups: 
Interim analyses and data monitoring
An independent Data and Safety Monitoring Committee (DSMC) was established to monitor the occurrence of serious clinical and biological events. The DSMC reviewed unblinded data to examine patient characteristics, treatment compliance, outcomes and safety events once the first 100 patients had completed 12 months of follow-up. Only DSMC members and statisticians compiling closed-session reports for board meetings have had access to unblinded interim data and results. The Haybittle-Peto boundary was used as a stopping guideline for efficacy to maintain an overall type I error rate of 5% level [15] . The incidence of distant intracranial failure over time was calculated using a risk analysis accounting for extracranial melanoma progression and death from any cause other than intracranial disease as competing risks. Distant intracranial failure and death from intracranial disease were counted as events. After the interim review, the DSMC made the following recommendation in the closed minutes: The quality of the data collection for the major endpoints of this study were meeting an excellent standard, the pre-specified stopping criteria have not been met, and recommended continuation of the study.
Multinational multicentre study
This is a trial involving three countries (Australia, Norway and the UK) in which 24 centres have contributed data for at least one patient. Although study centres were included as a stratification factor in the randomisation scheme, analyses of primary and secondary efficacy outcomes will not adjust for study centre, because it is anticipated some centres may be too small and may not contribute any events to the pooled data. However, if a positive treatment effect on the primary composite outcome or the component events emerges, study centres will be combined by country (Australia, Norway and the UK) to assess the homogeneity of the treatment effect across countries. Potential heterogeneity will be tested by including a treatment-by-country interaction term in a multivariate model with treatment and country as the main effects.
Data analysis
Demographic and baseline variables
A description of the following baseline characteristics will be presented by treatment group. All continuous variables will be summarised using the following descriptive statistics: n NCF assessments X X X X X X X X X X X X X X X X X X X X X 
Process measurement
The summary statistics will be produced in accordance with the Demographic and baseline variables section by follow-up visit (baseline, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 months). Differences between groups at each follow-up visit will be assessed using the mean difference and its 95% CI for continuous variables and the odds ratio along with the corresponding 95% CI for categorical variables. The overall treatment effect will be estimated using repeated measures mixed linear model (MLM) analysis or generalised estimating equation (GEE) methods as appropriate. The following variables will be summarised: 
Efficacy analyses
Efficacy analyses will be conducted on the basis of 'intention to treat' and will be stratified by treatment group. Efficacy analysis will be adjusted with the four stratification factors (one vs. more than one cerebral metastasis, presence of extracranial disease vs. none, patients aged < 65 years of age or ≥ 65 years of age, sex: male vs. female). All group comparisons will be twotailed with a 5% significance level. For efficacy time-toevent outcomes, patients with incomplete follow-up who did not experience a relevant outcome event will be censored at the time of their last contact (that is, their time data will contribute to analyses).
Primary outcome
The primary endpoint, defined as distant intracranial failure within 12 months of follow-up (binary failure/success), will be compared using a Pearson chi-squared test. In cases where the expected count per cell is less than 5, Fisher's exact test will be used. Overall treatment effect will be summarised using the odds ratio and its 95% CI). Absolute treatment effect (risk difference) will also be computed. Treatment success was defined as patients who did not experience distant intracranial failure within 12 months after starting treatment. Patients who died prior to the 12 months assessment without any distant intracranial failure sign will also be considered as a success. In addition, patients who experienced local failure but died without clinical evidence of distant failure will be recorded as a success. When patients have withdrawn consent or have been lost to follow-up before the 12 months assessment, the last follow-up intracranial assessment status will be used for the primary endpoint analysis.
Key secondary outcomes
Neurocognitive endpoint is defined as decline in the mean raw score of the Hopkins Verbal Learning TestRevised (HVLT-R) Delayed Recall at 4 months, using mean relative change and Reliable Change Index (RCI).
The Global Deficit Score (GDS) derived from NCF tests at each assessment point where cognitive impairment is defined as a GDS of ≥0.5. The proportion of patients with cognitive impairment in each group (Observation, HA-WBRT and WBRT) will be summarised by frequency and rate with its two-sided 95% Clopper-Pearson exact CI. The denominator will be defined as the total number of patients for whom the GDS is computed. No formal inference will be performed given the study is not designed for a formal comparison between groups. Table 2 shows the calculation of GDS.
Secondary outcomes
We will analyse distant intracranial failure at 3, 6 and 9 months and over the entire study follow-up period, and local intracranial failure and overall intracranial failure at 3, 6, 9 and 12 months and over the entire study follow-up period. Analysis will be produced in accordance with the primary outcome.
Time-to-event outcomes All secondary time-to-event outcomes with the exception of overall survival and time to deterioration in performance status will be analysed in the context of the competing risks [16] . For instance, death from any other cause than intracranial disease will prevent observation of a distant intracranial event. Therefore, the incidence of distant intracranial failure over time will be calculated using risk analysis accounting for death from any cause other than intracranial disease as a competing risk. The incidence of intracranial events between the treatment and observation arms will be compared using Gray's test for equality while accounting for competing risks (non-intracranial death) [17] . Other time-to-event endpoints include time to local intracranial failure (competing with both death or distant failure as local failure is captured only before distant failure), time to overall (first distant or local) intracranial failure (competing with death), time to melanoma death (competing with non-melanoma death) and time to intracranial death (competing with other causes of death). These endpoints will also be analysed using a competing risks approach. In addition, all time-to-event outcomes will be summarised graphically over the entire study follow-up period through (1) Kaplan-Meier methods with log-rank test stratified with the four stratification factors to assess the differences between treatment arms and (2) a cumulative incidence function for competing risk outcomes, with Gray's test for differences between treatment arms. Hazard ratios using the Cox proportional hazard model stratified with the four stratification factors, or subdistribution hazard ratios using the Fine and Gray model adjusted with the four stratification factors and their associated 95% CIs will be displayed in corresponding figures as appropriate.
Overall survival The outcome will be described using the product limit method of Kaplan-Meier. Survival curve distribution differences between treatment groups will be tested using the log-rank test. Hazard ratios and corresponding 95% CIs will be computed using the Cox proportional hazard model. The validity of the proportional hazards assumption will be tested using Schoenfeld residuals plots and corresponding test statistics. In contrast, if the proportional hazard assumption is violated (i.e. the hazard ratio is changing over time), an alternative robust measure known as restricted mean survival time (RMST), which does not rely on a specific assumption, will be generated in each arm. Then instead of hazard ratio, the difference in RMST along with its 95% CI will be computed to evaluate the potential benefit of WBRT effects over the study duration.
Time to deterioration in performance status The analysis will be produced in accordance with the overall survival outcome analysis.
Time to deterioration in health-related quality of life (QoL) parameters This outcome is measured by EORTC QLQ-C30 with Brain Cancer Module (EORTC QLQ-BN20) questionnaires. The completion rates for quality of life questionnaires (QLQs) at the baseline visit and at each 2 monthly follow-up visit will be determined for each treatment group together with descriptive summaries of scores. The cumulative incidence function will be used to describe patterns of deterioration in healthrelated QoL. A significant difference between groups will be tested using Gray's test.
QoL outcomes Utility-based QoL will be derived from QLQ-C30 using the McKenzie mapping algorithm. EQ-5D-5 L utilities will be calculated using the Australian tariff [18] . The continuous utility endpoints will be summarised by mean (SD) and stratified by assessment time points (baseline, 2-48 months) and by treatment group [19] . The mean difference between the two arms and their corresponding 95% CI will be provided at each assessment time point. The average effect of the intervention on each continuous outcome, over the entire study period, will be estimated through an MLM with random intercept, adjusting with associated baseline score, time (categorical) and interaction between treatment and time. In addition, an estimate of the intervention effect adjusted for the four stratification factors (one vs. more than one cerebral metastasis, presence of extracranial disease vs. none, patients age < 65 vs. ≥ 65 years old, and sex: male vs. female) will also be reported.
Categorical dimension/items will be analysed using Likert-type scales and stratified by treatment group.
Deterioration in neurocognitive function (NCF)
The main NCF endpoint will be defined as a decline in the mean score of the HVLT-R Delayed Recall at pre-specified follow-up visits. The proportion of patients completing NCF assessments at the baseline visit and at each 2 monthly follow-up visit will be determined for each of the treatment groups (WBRT and Observation) together with a descriptive summary of raw, standardised Zscores, a composite Z-score and GDS scores. The summary statistics will be produced in accordance with the Process measurement section by follow-up visit (2, 4, 6, 8, 10 and 12 months). These will be standardised adjusting for age, education and gender, and analysed for change from baseline to pre-specified assessment visit. Decline will be defined using the RCI [6, 7] and will also be compared between the arms. Mean score changes and 95% CI will also be represented graphically from baseline over time. The overall effect of the intervention on each continuous NCF variable will be estimated through an MLM with random intercept, adjusting with associated baseline score, time (categorical) and also interaction between treatment and time. Overall effect for categorical NCF variables will be estimated using GEE regression with a log-binomial link. The following variables will be summarised: All analyses will be based on available data (complete case). However, if more than 10% of the data are missing for an outcome, a multiple imputation method will be carried out as a sensitivity method assuming data are missing at random (MAR). The MAR assumption indicates that the missingness mechanism depends on the observed outcome but not on the missing outcome, which seems an appropriate assumption in this study [20] .
Exploratory analyses will be conducted adjusting for prognostic factors. Other time-to-event endpoints will also be analysed using similar methods. Time to deterioration in NCF will be analysed using both raw and standardised scores and defined by a significant change in the RCI (decline of ≥ 5 points from baseline). Outcomes will be analysed using a competing approach assuming deterioration in NCF is competing with any failure (local/distant intracranial failure or death).
Exploratory efficacy analyses Subgroup analysis
The subgroup analyses will assess potential differences in treatment effects, through an interaction effect. Evidence of heterogeneity of treatment effects among subgroups will be demonstrated by the level of statistical significance of the interaction term between treatment group and subgroup using either a logistic regression (for a binary outcome) or Cox regression (Overall survival) using a threshold of significance of 0.05. The subgroup analyses will remain exploratory and hypothesisgenerating given the study is not specifically powered to test any subgroup. Results will be presented as forest plots with P values for heterogeneity (interaction test) for each pair of subgroups displayed.
Tertiary endpoints
Exploratory analysis will be performed by simultaneously comparing Observation vs. HA-WBRT vs. WBRT on the variables listed below. Time-to-event outcomes will be analysed in accordance with the Efficacy Analyses section using a competing risks model or the Cox proportional hazard model as appropriate. The cumulative incidence function or Kaplan-Meier survival curves will be provided as appropriate. Test of difference between the three groups will be performed using one-way analysis of covariance (ANCOVA) for continuous variables. For categorical variables, GEE regression with a log-binomial link will be used. All models will be adjusted with their baseline measurements and will include the following variables: Deterioration in NCF will be represented graphically from baseline over time.
The preceding analysis will be replicated by the stratification factors: one vs. more than one cerebral metastasis, presence of extracranial disease vs. none, < 65 years vs. ≥ 65 years of age, and sex: male vs. female.
Safety analyses
Safety outcomes will be analysed via frequencies for the number of episodes of adverse events (AEs) and via frequencies and percentages for the number of patients with at least one episode per cohort (with the denominator being the total number of patients in each group).
All AEs (graded per Common Terminology Criteria for Adverse Events [CTCAE]), even those not analysed, will be reported stratified by treatment arm.
Conclusion
We have developed a statistical analysis plan (SAP) for the ANZMTG 01.07 WBRTMel study. This plan will be followed to ensure high-quality standards of internal validity to minimise analysis bias. The SAP was approved and signed off by the Trial Management Committee on 1 October 2018. Following data integrity checks of the primary and secondary 12 months outcomes, the statistical analysis specified in the SAP was started January 2019.
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